The @-year survival rate for ipilimumab plus sargramostim was @ % ( @ % CI , @ % -@ % ) compared to @ % ( @ % CI , @ % -@ % ) for ipilimumab alone ( stratified log-rank @-sided P = @ ; mortality hazard ratio @ -LSB- @-sided @ % repeated CI , not applicable-@ @ -RSB- ) .